Home Top Movers Aldeyra Therapeutics, Inc. (ALDX) Stock Prices Surge After News of Clinical Trial...

Aldeyra Therapeutics, Inc. (ALDX) Stock Prices Surge After News of Clinical Trial Success

Aldeyra Therapeutics, Inc. (ALDX) stock prices were up 4.81% as of market close on April 26th, 2021 bringing the price per share up to USD$11.11. Subsequent pre-market fluctuations have seen the stock price surge by 21.78%, bringing it up to USD$13.53.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Success of INVIGORATE Clinical Trial

The sharp increase in ALDX stock prices came hot on the heels of the news of positive top-line results from the third phase of INVIGORATE Clinical Trial, reproxalap. The IND designed as a treatment for patients with allergic conjunctivitis was the source of resounding success when the clinical trials successfully achieved statistical significance for its primary endpoint, as well as for every secondary endpoint.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Read More

What’s Next for INVIGORATE?

The company hopes to submit a New Drug Application in the second half of 2021 following a discussion with the U.S. Food and Drug Administration in regard to INVIGORATE results from clinical trials. Current and prospective investors are hopeful that things will go smoothly and the eventual commercialization of reproxalap will bear fruit for both the company and its shareholders.

ALDX’s Public Offering

ALDX announced the completion of its public offering at the beginning of 2021, wherein it put up 7,868,421 shares of its common stock for sale at USD$9.50 per share. Underwriters were also granted the option to purchase up to 1,026,315 shares of common stock in the event of over-allotments. The offering generated USD$74.7 million in gross proceeds with USD$4.7 million in costs associated with the offering. The funds will be allocated primarily to the development of reproxalap, as well as other product candidates.

Funding the Future

In addition to the funds generated from the offering, ALDX has reported having cash and cash equivalents equaling USD$77.9 million as of December 31st 2020. With such a solid liquidity position the company anticipates being able to sustain itself through to the end of 2023, with enough funds to ensure the funding of its many clinical trials currently underway.

Myriad of Clinical Trials Underway

Of the many clinical trials in varying stages of completion, TANQUILITY and TRANQUILITY-2 are clinical trials for the treatment of dry eye disease and are in Phase 3; whereas the GUARD clinical trial I in the first part of its adaptive Phase 3 in proliferative vitreoretinopathy. Furthermore, the company is working on Phase 2 clinical trials of ADX-629 for the treatment of psoriasis, atopic asthma, and, perhaps most significantly, COVID-19.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Future Outlook for ALDX

With hugely successful completion of the INVIGORATE clinical trial, a sound liquidity position, and diversification into the treatment of the global COVID-19 pandemic, ALDX is situated to have a prosperous 2021. Investors are hopeful for the continued success of clinical trials and expect to see the company manage to significantly sustain growth in shareholder value.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

What Explains MOGO Stock Going Up Today?

The Mogo Inc. (NASDAQ: MOGO) stock has gained 5.04% to $8.55 in premarket trading today. Mogo stock finished last trading day at $8.14, down...

Zynga Inc. (ZNGA) stock rises in the Pre-Market: What’s going on?

Zynga Inc. (ZNGA) announced its first-quarter 2021 financial results after which the ZNGA stock happened to be green after underperformance in the last trade....

American Shared Hospital Services (AMS) Stock Continues to Soar Following Unprecedent Volumes Being Traded

American Shared Hospital Services (AMS) stock prices surged by 30.51% as of market close on May 5th, 2021, bringing the price per share up...

James River Group Holdings Ltd. (NASDAQ: JRVR) stock falls during pre-market. Why is it so?

James River Group Holdings Ltd. (NASDAQ: JRVR) stock plunged by 1.67% at last close while the JRVR stock continued decline by 25.74% at last...

Aviat Networks, Inc. (AVNW) Stock Trending Up After Promising Financial Reports for Most Recent Quarter

Aviat Networks, Inc. (AVNW) stock prices were up 3.81% as of market close on May 5th 2021, bringing the price per share up to...

Ambev S.A. (ABEV) Stock Trends Up Following Highly Promising Earnings Call for Q4 2020

Ambev S.A. (ABEV) stock prices were up 10.3943% shortly after the market opened on May 6th, 2021, bringing the price per share up to...

Sally Beauty Holdings (NYSE:SBH) stock surged in the current trading session; here’s why

In the current trading session, Sally Beauty Holdings Inc. (SBH) stock had surged by 19.69% to $24.25 at the time of writing. SBH stock...

Moderna Inc. (NASDAQ: MRNA) stock declines during current market. Let’s figure out why?

Moderna Inc. (NASDAQ: MRNA) stock falls by 5.31% in the current market trading after MRNA has announced its financial results for Q1 2021. Moderna...

Related News

Himax Technologies, Inc. (HIMX) Stock Climbing After Promising Q1 2021 Financial Reports

Himax Technologies, Inc. (HIMX) stock prices were down by 6.97% as of the market closing on May 5th 2021, bringing the price per share...

Why BioCryst Pharmaceuticals, Inc. (BCRX) stock is climbing today?

BioCryst Pharmaceuticals, Inc. (BCRX) announced its first-quarter 2021 financial results after which the BCRX stock happened to be green as its per-share price went...

Precipio, Inc. (PRPO) Stock Trending Up Following Successful Launch of Covid-19 Antibody Testing Kit

Precipio, Inc. (PRPO) stock prices were down 3.62% as of the market closing on ay 5th 2021, bringing the price per hare down to...

Shares of Cinedigm Corp. (CIDM) are climbing high in the premarket. What’s Going On?

Cinedigm (NASDAQ:CIDM), a distributor of various movies, television and other digital content, managing a library of distribution rights to several thousand titles and different...

Why Stealth BioTherapeutics Corp (MITO) stock is soaring in Pre-Market today?

Stealth BioTherapeutics Corp (MITO) presented the data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting, which is collected...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.